fda warning letter compounding semaglutide october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Novo Nordisk Calls for FDA

The whole appeal of KLOW is one clean draw

Changes in PMS Symptoms: Breast tenderness, cramps, and mood swings may be brought about Semaglutide to be more severe or milder in very few cases due to its regulating power over the hormones

Targher G, Lonardo A, Byrne CD

Statin use changes the gut microbiome in a way that reduces GLP-1 production.[ref] Statins are one of the top drugs prescribed each year

The program also includes tailored advice on lifestyle and diet to complement medication

Notably, the cardiovascular outcomes study conducted on adults (SELECT study) revealed a higher incidence of hip and pelvic fractures among female patients receiving semaglutide compared to those on placebo: 1.0% (24/2448) versus 0.2% (5/2424) [80]